A home-based cardiac rehabilitation program can be substituted for a supervised, center-based program for low-risk patients.153,159,160 (Level of Evidence: A) Class IIa 1. A comprehensive exercise-based outpatient cardiac rehabilitation program can be safe and beneficial for clinically stable outpatients with a history of heart failure.159,159a 159c (Level of Evidence: B) JNC indicates the report of the National Heart, Lung, and Blood Institute s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines; ACE, angiotensin-converting enzyme; ATP, Adult Treatment Panel; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; INR, international normalized ratio; and ARB, angiotensin receptor blocker. *Presence of established CVD plus (1) multiple major risk factors (especially diabetes), (2) severe and poorly controlled risk factors (especially continued cigarette smoking), (3) multiple risk factors of the metabolic syndrome (especially high triglycerides $200 mg/dL plus non HDL-C $130 mg/dL with low HDL-C ,40 mg/dL), and (4) patients with ACSs. Non HDL-C5total cholesterol minus HDL-C. The use of bile acid sequestrants is relatively contraindicated when triglycerides are $200 mg/dL and is contraindicated when triglycerides are $500 mg/dL. Dietary supplement niacin must not be used as a substitute for prescription niacin. \The combination of high-dose statin plus fibrate (especially gemfibrozil) can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury. #Estimated creatinine clearance should be .30 mL/min. **Potassium should be ,5.0 mEq/L. clinical depression/depression screening; and cardiac/car- diovascular rehabilitation. Additional searches cross- referenced these topics with the subtopics of clinical trials, secondary prevention, atherosclerosis, and coronary/cerebral/pe- ripheral artery disease. 